Literature DB >> 20616270

HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.

Didier Trono1, Carine Van Lint, Christine Rouzioux, Eric Verdin, Françoise Barré-Sinoussi, Tae-Wook Chun, Nicolas Chomont.   

Abstract

HIV infection can persist in spite of efficacious antiretroviral therapies. Although incomplete inhibition of viral replication may contribute to this phenomenon, this is largely due to the early establishment of a stable reservoir of latently infected cells. Thus, life-long antiviral therapy may be needed to control HIV. Such therapy is prone to drug resistance and cumulative side effects and is an unbearable financial burden for regions of the world hit hardest by the epidemic. This review discusses our current understanding of HIV persistence and the limitations of potential approaches to eradicate the virus and accordingly pleads for a joint multidisciplinary effort toward two highly related goals: the development of an HIV prophylactic vaccine and the achievement of long-term drug-free remissions in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616270     DOI: 10.1126/science.1191047

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  155 in total

1.  Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.

Authors:  Mario Stevenson; Nicolas Chomont; Alain Lafeuillade
Journal:  AIDS Res Ther       Date:  2012-03-12       Impact factor: 2.250

2.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 3.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

4.  Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.

Authors:  Suzanne M Tomlinson; Stanley J Watowich
Journal:  Antiviral Res       Date:  2010-12-23       Impact factor: 5.970

Review 5.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

6.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 7.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 8.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

9.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  Interleukin-7 promotes HIV persistence during antiretroviral therapy.

Authors:  Claire Vandergeeten; Rémi Fromentin; Sandrina DaFonseca; Mariam B Lawani; Irini Sereti; Michael M Lederman; Moti Ramgopal; Jean-Pierre Routy; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.